Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The first MRC-DTP Symposium took place on 22 June 2017 in the Richard Doll Building at the Old Road Campus. The symposium was an opportunity for Medical Research Council funded students to network as well as present their research to peers. With sponsorship from Fisher Scientific and the Nuffield Department of Population Health, 52 people attended the symposium.

The MRC DTP Steering Group Chair, Prof. Marella de Bruijn opened the day and the first session featured talks from Ulrike Kuenzel, Soren Thomsen and Josephine Hellberg. The second session, chaired by Paolo Spingardi, brought together Jan Cosgrave, Abigail Enoch and Daniel Alanine. During the lunch break, poster sessions took place allowing researchers to showcase their work in an informal setting whilst providing a basis for discussion and networking. The afternoon had two parallel training sessions- a Managing Your Supervisor workshop led by Afsie Sabokbar, and a CV workshop from Michael Moss of the University of Oxford, Careers Service. The symposium closed with a ‘Speed Science’ session (think speed dating with science) followed by a wine reception.

Symposium3

Symposium participants commented:

“Good opportunity to present work to local and informal audience, good prep for conferences etc. Also interesting breadth of research.”

“The CV workshop was supreme and it was so wonderful networking with fellow MRC students and hearing about their work.

"Interesting to hear about different research being done; interesting to hear more about the MRC-DTP program”

With thanks to the Organising Committee:

Joost van Haasteren
Jessica Valli
Marella de Bruijn
Laura Colling
Marc Rose

Thanks also to Paolo Spingardi who provided assistance on the day. 

 

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.